VAS
RARE icon

Vestmark Advisory Solutions’s Ultragenyx Pharmaceutical RARE Stock Holding History

Vestmark Advisory Solutions’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,277
Closed -$222K – 661
2024
Q4 		$222K Sell
5,277
-668
-11% -$33.1K 0.01% 547
2024
Q3 		$330K Hold
5,945
– – 0.01% 431
2024
Q2 		$244K Buy
+5,945
New +$254K 0.01% 492
2021
Q2 		– Sell
-2,250
Closed -$256K – 798
2021
Q1 		$256K Buy
+2,250
New +$306K 0.02% 644

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vestmark Advisory Solutions's RARE Position: Q1 2025 in Review

Vestmark Advisory Solutions sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 5,277 shares — an estimated $222K sold.

Vestmark Advisory Solutions first reported a position in RARE in Q1 2021 and held it in 4 quarters. The position peaked at $330K in Q3 2024. 299 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

  • Vestmark Advisory Solutions reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Vestmark Advisory Solutions sold 5,277 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $222K.
  • Vestmark Advisory Solutions first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 4 quarters.
  • Vestmark Advisory Solutions's Ultragenyx Pharmaceutical position peaked at $330K in Q3 2024.
  • 299 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on Vestmark Advisory Solutions's 13F filing for Q1 2025, filed 13 May 2025.